Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising.
MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF) has completed and delivered its first Edge AI Intoxication and Fatigue Detection Kiosk prototypes, advancing its efforts to commercialize voice-based impairment detection technology for workplace safety applications. The kiosks use artificial intelligence to analyze short voice samples for more than 140 acoustic markers associated with potential alcohol, drug or fatigue-related impairment, with models trained on more than 50 million data points. The prototypes are now entering testing, validation and data-analysis phases involving industry participants, speech specialists and software engineers as the company works to refine its predictive models and assess real-world performance. MindBio is targeting safety-sensitive industries including mining, aviation, construction, transportation and law enforcement, where large workforces and operational risks can make conventional breath, saliva, urine and laboratory testing costly and time-consuming. The company’s approach is designed to provide rapid, scalable and less invasive initial screening, with individuals flagged for potential impairment able to undergo additional evaluation using established testing protocols.
To view the full article, visit https://ibn.fm/R2OqM
About MindBio Therapeutics Corp.
MindBio is a biotechnology company that is commercializing AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement.
For more information, visit the company’s website at www.MindBioTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to MBQIF are available in the company’s newsroom at https://ibn.fm/MBQIF
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
